Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yun-Xing Cheng is active.

Publication


Featured researches published by Yun-Xing Cheng.


Bioorganic & Medicinal Chemistry Letters | 2008

Novel benzimidazole derivatives as selective CB2 agonists.

Daniel Page; Elise Balaux; Luc Boisvert; Ziping Liu; Claire Milburn; Maxime Tremblay; Zhongyong Wei; Simon Woo; Xuehong Luo; Yun-Xing Cheng; Hua Yang; Sanjay Srivastava; Fei Zhou; William Brown; Miroslaw Tomaszewski; Christopher Walpole; Leila Hodzic; Stephane St-Onge; Claude Godbout; Dominic Salois; Keymal Payza

The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.


Organic Letters | 2010

Practical synthesis of quinoxalinones via palladium-catalyzed intramolecular N-arylations.

Xuehong Luo; Etienne Chénard; Peter Martens; Yun-Xing Cheng; Miroslaw Tomaszewski

A practical and highly efficient route to the synthesis of pharmaceutically interesting quinoxalinone scaffolds is reported. The key step involves an intramolecular palladium-catalyzed N-arylation under microwave irradiation. The developed methodology tolerates a variety of bromoanilides to afford a diverse collection of bicyclic and polycyclic quinoxalinones in high yield.


Bioorganic & Medicinal Chemistry Letters | 2012

γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.

Yun-Xing Cheng; Mehrnaz Pourashraf; Xuehong Luo; Sanjay Srivastava; Christopher Walpole; Dominic Salois; Stephane St-Onge; Kemal Payza; Etienne Lessard; Xiao Hong Yu; Miroslaw Tomaszewski

An oral, peripherally restricted CB1/CB2 agonist could provide an interesting approach to treat chronic pain by harnessing the analgesic properties of cannabinoids but without the well-known central side effects. γ-Carbolines are a novel class of potent mixed CB1/CB2 agonists characterized by attractive physicochemical properties including high aqueous solubility. Optimization of the series has led to the discovery of 29, which has oral activity in a rat inflammatory pain model and limited brain exposure at analgesic doses, consistent with a lower risk of CNS-mediated tolerability issues.


Archive | 2006

NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS

Yun-Xing Cheng; Miroslaw Tomaszewski


Archive | 2007

Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia

Yun-Xing Cheng; Shujuan Jin; Mehrnaz Pourashraf; Miroslaw Tomaszewski


Archive | 2007

Isoindole derivatives useful for treating pain, gastrointestinal diseases and cancer

Yun-Xing Cheng; Miroslaw Tomaszewski; Hua Yang


Archive | 2008

Piperidine derivatives as agonists of muscarinic receptors

Yun-Xing Cheng; Xuehong Luo; Vijayaratnam Santhakumar; Miroslaw Tomaszewski


Archive | 2008

New compounds 966

Yun-Xing Cheng; Xuehong Luo; Vijayaratnam Santhakumar; Miroslaw Tomaszewski


Archive | 2007

Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's decease and/or schizophrenia

Yun-Xing Cheng; Xuehong Luo; Miroslaw Tomaszewski


Archive | 2009

NOVEL COMPOUNDS-300

Yun-Xing Cheng; Vijayaratnam Santhakumar; Miroslaw Tomaszewski

Collaboration


Dive into the Yun-Xing Cheng's collaboration.

Researchain Logo
Decentralizing Knowledge